Debiopharm Group

What Debiopharm Group does

Debiopharm Group is an independent, family-controlled Swiss biopharmaceutical company founded in 1979 and headquartered in Lausanne, operating through three integrated divisions: drug development (Debiopharm International), GMP drug manufacturing (Debiopharm Research & Manufacturing, FDA-inspected facility in Martigny), and a strategic digital health investment arm (Debiopharm Innovation Fund, approximately USD 100 million deployed since 2008 across ~14 portfolio companies). The core business model is in-licensing of early-stage compounds from universities and biotech startups, internal development through clinical stages using proprietary technology platforms, and out-licensing to global pharmaceutical partners — including Ipsen, Takeda, Merck KGaA, Ferring, Yakult, and ITM — for worldwide commercialization in exchange for milestone payments and royalties. The firm has produced two historically blockbuster therapies (oxaliplatin/Eloxatin and triptorelin/Decapeptyl) and currently maintains approximately 15 active R&D programs.

The proprietary technology base centers on three platform families. DEBIO SPHERES is a world-leading PLGA-based injectable sustained-release technology powering marketed 1/3/6-month triptorelin formulations and the in-development 12-month formulation Debio 4326. The MultiLINK platform offers a modular suite of tunable, peptide-based, cathepsin B-cleavable ADC linkers supporting high DAR (up to DAR 16) and dual-payload delivery via MLINK Duo (DAR 8+8). AbYlink is a non-enzymatic, site-specific antibody conjugation technology attaching payloads or imaging agents to the Fc region of any IgG in under one hour under GMP-compatible conditions. The clinical pipeline spans oncology (lunresertib/PKMYT1 and zedoresertib/WEE1 inhibitors with FDA Fast Track Designation; multiple ADC candidates including Debio 1562M for AML/MDS; Debio 0532 for HER3-positive solid tumors; Debio 2512 bispecific ADC), endocrinology (Debio 4126 quarterly octreotide for acromegaly in Phase III), and infectious disease (Debio 1453, a first-in-class FabI inhibitor for Neisseria gonorrhoeae developed in partnership with GARDP for global access). The firm operates at approximately 420 employees under the parent holding company Après-demain SA, with the Mauvernay family maintaining ownership and Thierry Mauvernay serving as President alongside CEO Bertrand Ducrey.

Commercially, Debiopharm monetizes through milestone payments and royalties from out-licensed products, contract manufacturing services from its FDA-inspected facility, and equity-driven returns from the Innovation Fund's digital health portfolio (notable historical exits include Kaiku Health to Elekta in 2020 and Voluntis to AptarGroup in 2021). The strategic posture emphasizes platform reusability — PLGA sustained-release, ADC conjugation, and linker chemistry are applied across multiple programs — and selective AI integration through external partnerships (Genialis for biomarker discovery, Risklick for protocol authoring, NetTargets for ADC target identification, ViewsML for virtual biomarker staining from pathology). Geographic reach spans Europe, North America, and selected LATAM and APAC markets for clinical operations, with global commercialization executed exclusively through licensing partners rather than direct sales infrastructure.

Name

Debiopharm Group

Legal name

Debiopharm International SA

Website

http://www.debiopharm.com/

Company type

Private

Founded year

1979

Operating status

Operating

Headcount range

251–500 employees

Short description

Debiopharm Group is a Swiss biopharmaceutical company that in-licenses early-stage oncology and infectious disease compounds, develops them through clinical stages using proprietary sustained-release and ADC platforms, and out-licenses them to global pharma partners such as Ipsen, Takeda, and Merck KGaA for commercialization.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Drug Development

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

akta.pro secondary industries

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• Biopharmaceutical development
• Clinical drug development
• Sustained-release formulations
• Antibody-drug conjugates
• Digital health investment

Headquarters

HQ city

Lausanne

HQ country

Switzerland

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain

Revenue model

1. Drug Development and Out-Licensing: Debiopharm in-licenses innovative compounds from universities or start-ups, develops them through clinical stages, and out-licenses to pharmaceutical partners for worldwide commercialization. Revenue generated through milestone payments and royalties from commercialization partners.
2. Drug Manufacturing: Debiopharm Research & Manufacturing operates as a pharmaceutical research, development and production facility, inspected and registered with main regulatory authorities, providing manufacturing services.
3. Digital Health Investment: Debiopharm Innovation Fund invests in digital health and smart data start-ups, providing strategic funding and gaining equity stakes in portfolio companies.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Debiopharm in-licenses early-stage biologics and small-molecule compounds from universities and start-ups, develops them through preclinical and clinical stages using proprietary drug delivery platforms (PLGA-based DEBIO SPHERES sustained-release, MultiLINK ADC linkers, AbYlink antibody conjugation), and out-licenses to global pharmaceutical partners for commercialization. The group operates an FDA-inspected drug manufacturing facility in Martigny and a digital health investment fund backing AI/data start-ups.

Product overview

Debiopharm Group operates as an independent biopharmaceutical company with three divisions: drug development (Debiopharm International), drug manufacturing (Debiopharm Research & Manufacturing), and digital health investment (Debiopharm Innovation Fund). Its core product offerings span proprietary drug delivery technology platforms and a clinical-stage pipeline of targeted oncology and infectious disease therapies. The drug delivery portfolio is anchored by the DEBIO SPHERES™ PLGA-based sustained-release platform (used in marketed products Decapeptyl®/Pamorelin® and clinical candidates Debio 4126 and Debio 4326), the AbYlink™ antibody conjugation technology, and the MultiLINK™ ADC Technology Suite (including MLINK Duo for dual-payload delivery). The clinical pipeline includes CD37 ADCs (Debio 1562M in Phase I/II for AML/MDS, Debio 1562), HER3/HER2 ADCs (Debio 0532, Debio 2512), DDR inhibitors (lunresertib/PKMYT1 and zedoresertib/WEE1, Fast Track Designated 2026), and antibiotics (Debio 1453 in Phase I for gonorrhea). The Innovation Fund invests in digital health/AI startups including Genialis (AI biomarker discovery), ViewsML (virtual biomarker staining), and Risklick (protocol AI). Debiopharm in-licenses early-stage compounds, develops them through clinical stages, and out-licenses to global pharmaceutical partners.

Differentiator

Problem solved

Functional benefit

Brands

• AbYlink: Proprietary antibody conjugation technology platform developed by Debiopharm for developing antibody-drug conjugates (ADCs).
• MultiLINK

Products and services

• Decapeptyl / Pamorelin (Triptorelin)

Quantifiable outcome

• Two blockbuster therapies developed and commercialized worldwide (oxaliplatin, triptorelin with combined sales exceeding $1.8 billion in 2004)

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

Partnerships

15 partnerships are on record, tiered core and strategic.

• GARDP (Global Antibiotic Research and Development Partnership)coreStrategic or Co-development Partner · 13 January 2026Collaboration and license agreement to pursue development of Debio 1453, a novel first-in-class antibiotic targeting Neisseria gonorrhoeae. GARDP leads non-clinical and clinical development activities and CMC, while Debiopharm completes Phase I trial. GARDP granted manufacturing and commercialization rights in 160+ countries for global access.
• GenialisstrategicTechnology or Integration · 11 January 2026Debiopharm deploying Genialis software to support AI-driven biomarker discovery, leveraging AI and data management technologies for precision medicine development.
• ITM Isotope Technologies Munich SEstrategicStrategic or Co-development Partner · 4 December 2025Collaboration on Phase 1/2 trial evaluating ITM-94 as diagnostic agent for clear cell renal cell carcinoma. ITM and Debiopharm announced first patient imaged in new study arm.
• NetTargetscoreStrategic or Co-development Partner · 30 October 2025Strategic research collaboration to develop next-generation dual-payload ADCs for drug-resistant cancers. Combines NetTargets' AI discovery platform with Debiopharm's MLINK Duo technology for synergistic drug combinations and coordinated delivery of two distinct warheads.
• RisklickstrategicTechnology or Integration · 16 October 2025Pilot collaboration using Risklick's Protocol AI software for clinical trial protocol development. Successful proof-of-concept completed to generate robust clinical protocols within structured environment.
• Alkyon TherapeuticsstrategicStrategic or Co-development Partner · 12 June 2025Research collaboration to advance next-generation radioligand therapies, combining expertise in radiochemistry and drug delivery technologies.
• Oncodesign ServicesstrategicTechnology or Integration · 24 April 2025Strategic collaboration to advance radiopharmaceuticals in preclinical research, combining Oncodesign's specialized expertise with Debiopharm's radiopharmaceutical development capabilities.
• Genome & CompanycoreOEM/ Whitelabel/ Licensing PartnerLicensing deal for novel target ADC (now Debio 0633) targeting IND filing by late 2027-2028. Part of strategic shift from microbiome-focused biotech to first-in-class oncology drug developer.
• SunRock BiopharmacoreOEM/ Whitelabel/ Licensing PartnerExtended licensing agreement to develop HER3-EGFR bispecific ADCs (Debio 2512). Debiopharm licensed SunRock's anti-HER3/HER2 antibody to explore full potential of bispecific ADC development.
• IpsencoreChannel Partner/ Reseller/ DistributorLong-term commercialization partnership for Decapeptyl (triptorelin), one of Ipsen's leading marketed products. Major pharmaceutical partnership established over decades.
• TakedacoreChannel Partner/ Reseller/ DistributorRecent long-term commercialization partnership with Takeda for pharmaceutical products.
• Merck KGaAcoreChannel Partner/ Reseller/ DistributorLong-term commercialization partnership with Merck KGaA for pharmaceutical products.
• FerringcoreChannel Partner/ Reseller/ DistributorLong-term commercialization partnership with Ferring Pharmaceuticals.
• YakultcoreChannel Partner/ Reseller/ DistributorLong-term commercialization partnership with Yakult for pharmaceutical products.
• ITMcoreChannel Partner/ Reseller/ DistributorLong-term commercialization partnership with ITM for pharmaceutical products, including recent radiopharmaceutical collaboration.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Recordati: Italian specialty pharma with established brands in urology, endocrinology, and rare diseases, plus active in-licensing partnerships. Comparable to Debiopharm in mid-size specialty focus, reliance on partner-driven commercialization for select assets, and European family-controlled origins (until IPO).
• Mundipharma: Family-owned global specialty pharma network with deep European roots and focus on pain, oncology, and specialty therapeutics. Comparable to Debiopharm in private family-controlled structure, specialty focus, and partnership-driven market access.
• Ligand Pharmaceuticals: US biopharma operating a royalty-based business model by in-licensing or acquiring assets and capturing milestone/royalty economics. Directly comparable to Debiopharm's out-licensing revenue model and platform-licensing approach (e.g., MultiLINK, AbYlink, Captisol-style technology licensing).
• Ferring Pharmaceuticals: Swiss-headquartered privately-held specialty biopharma focused on reproductive health, urology, and gastroenterology. Highly comparable to Debiopharm in geographic origin, family-controlled governance, therapeutic areas (including triptorelin co-marketing relationship), and mid-size employee footprint.
• Ipsen: French specialty biopharma with overlapping therapeutic focus in oncology, urology, and rare diseases. Ipsen is Debiopharm's long-term commercialization partner for Decapeptyl (triptorelin) and a direct comparable in size, specialty focus, and out-licensing-driven pipeline strategy.

Broad incumbents

• UCB: Belgian specialty biopharma with mid-size employee footprint and focus on neurology, immunology, and rare diseases. Comparable to Debiopharm in European specialty focus, mid-cap scale, and licensing-oriented pipeline expansion.
• Takeda: Japanese global pharma with significant specialty and oncology franchises, and a long-term commercialization partner of Debiopharm. Broader incumbent but operates in overlapping therapeutic areas (oncology, rare diseases, GI).
• Sanofi: French global pharma and historical licensee of Debiopharm's oxaliplatin (Eloxatin). Operates a much broader portfolio but a relevant comparator in oncology commercial scale, manufacturing footprint, and out-licensing relationships with mid-sized developers.
• Merck KGaA: German global science and technology company with a healthcare division focused on oncology, neurology, and fertility. Long-term Debiopharm commercialization partner; broader incumbent with comparable therapeutic areas and out-licensing posture.

Emerging players

• ADC Therapeutics: Clinical-stage biopharma focused exclusively on ADC development for hematological and solid tumors. Directly comparable to Debiopharm's ADC pipeline (Debio 1562M, Debio 0532, Debio 2512) and represents a relevant pipeline-level peer despite Debiopharm's broader scope.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights8 records

Customer concentration

• LinkedInlinkedin.com/company/debiopharminternational
• Xx.com/DebiopharmHR
• Facebookfacebook.com/Debiopharm-Group

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Subsidiaries6 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments26 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Debiopharm Group